Yet, the prognosis is better than many investors assume.
That’s the collective view of the four panelists on Barron’s 2023 healthcare roundtable, who see enticing opportunities not only in the highflying shares of weight-loss giants (ticker: LLY) and Novo Nordisk (NVO) but also other pharma, biotech, hospital, and medical-device stocks that Wall Street has beaten down or ignored. Scientific breakthroughs, deal making, and a nimble response to regulation could brighten the industry’s financial prospects in the years ahead, these experts say, and reignite investor interest in one of the U.S. economy’s most important business drivers.
This year’s roundtable panelists include Ziad Bakri, a portfolio manager at T. Rowe Price and manager of the fund (PRHSX); Asad Haider, head of U.S. healthcare research and sector strategist at Goldman Sachs; Jared Holz, healthcare equity strategist at Mizuho; and Debra Netschert, a managing director at Jennison Associates and portfolio co-manager of fund (PHLAX). The group met with several Barron’s writers and editors on Zoom on Sept. 14 to share their views on this year’s biggest developments in healthcare, and on their favorite stocks.
